EMA, FDA To Address Quality Issues For PRIME/Breakthrough Designation Products

Experience with early access schemes in the EU and the US – i.e., PRIME and breakthrough therapy designation – has shown that sponsors face challenges in complying with quality and manufacturing data requirements.